EZR-104 Approval Status
EZR-104 (valsartan) is a novel formulation of the angiotensin receptor blocker valsartan, with patented RubiretenTM delivery technology, in development for the treatment of hypertension and heart failure.
Development Status and FDA Approval Process for EZR-104
|Jan 18, 2017||Ezra Announces FDA Acceptance of Filing of New Drug Application For EZR-104 for the Treatment of Hypertension and Heart Failure|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.